2026 Global: Alzheimer'S Disease Drug Market -Competitive Review (2032) report
Description
The 2026 Global: Alzheimer'S Disease Drug Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease drug market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease drug market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Eli Lilly and Company leads the Alzheimer's disease drug market with innovative anti-amyloid therapies like donanemab (Kisunla), approved by the FDA in 2024, alongside remternetug in advanced trials, positioning it as a frontrunner in disease-modifying treatments targeting amyloid plaques to slow cognitive decline. Biogen Inc. follows closely, co-developing Leqembi (lecanemab) with Eisai, which gained full FDA approval for early-stage Alzheimer's in 2025 and European authorization, generating $96 million in Q1 global sales despite past controversies with Aduhelm. Roche Holding AG advances trontinemab in Phase III TRONTIER trials for early symptomatic and preclinical Alzheimer's, emphasizing brain-penetrating Brainshuttle technology for robust amyloid reduction, complemented by diagnostics like Elecsys pTau217.
Novartis AG and AstraZeneca PLC maintain strong presences through extensive R&D in amyloid-targeting and neuroprotective strategies, with Novartis funding clinical trials amid rising demand for disease-modifying therapies. Johnson & Johnson bolstered its pipeline via a $14.6 billion acquisition of Intra-Cellular Therapies in April 2025, adding ITI-1284 for Alzheimer's agitation in Phase II, while historically contributing through Janssen's efforts. Pfizer Inc. co-markets legacy symptomatic drug Aricept (donepezil) with Eisai, generating $165 million in 2023 sales, and sustains involvement despite shifting focus to novel acquisitions in the surging Alzheimer's deal landscape totaling $16.8 billion by mid-2025.
Merck & Co. Inc., Bayer AG, and Amgen Inc. round out the top ten, investing in neurodegeneration pathways including tau and inflammation targets, with Amgen exploring biotech synergies. Sanofi S.A. expanded via $470 million Vigil Neuroscience buyout in May 2025 for TREM2 agonist VG-3927 in Phase II, following earlier investments, while AbbVie Inc. acquired Aliada Therapeutics for $1.4 billion in 2024, gaining ALIA-1758 for blood-brain barrier delivery of anti-amyloid antibodies. These companies drive market growth from $6.41 billion in 2025 to $19.3 billion by 2034 at 13.03% CAGR, fueled by acquisitions, innovations, and collaborations amid global prevalence surges.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease drug market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease drug market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Eli Lilly and Company leads the Alzheimer's disease drug market with innovative anti-amyloid therapies like donanemab (Kisunla), approved by the FDA in 2024, alongside remternetug in advanced trials, positioning it as a frontrunner in disease-modifying treatments targeting amyloid plaques to slow cognitive decline. Biogen Inc. follows closely, co-developing Leqembi (lecanemab) with Eisai, which gained full FDA approval for early-stage Alzheimer's in 2025 and European authorization, generating $96 million in Q1 global sales despite past controversies with Aduhelm. Roche Holding AG advances trontinemab in Phase III TRONTIER trials for early symptomatic and preclinical Alzheimer's, emphasizing brain-penetrating Brainshuttle technology for robust amyloid reduction, complemented by diagnostics like Elecsys pTau217.
Novartis AG and AstraZeneca PLC maintain strong presences through extensive R&D in amyloid-targeting and neuroprotective strategies, with Novartis funding clinical trials amid rising demand for disease-modifying therapies. Johnson & Johnson bolstered its pipeline via a $14.6 billion acquisition of Intra-Cellular Therapies in April 2025, adding ITI-1284 for Alzheimer's agitation in Phase II, while historically contributing through Janssen's efforts. Pfizer Inc. co-markets legacy symptomatic drug Aricept (donepezil) with Eisai, generating $165 million in 2023 sales, and sustains involvement despite shifting focus to novel acquisitions in the surging Alzheimer's deal landscape totaling $16.8 billion by mid-2025.
Merck & Co. Inc., Bayer AG, and Amgen Inc. round out the top ten, investing in neurodegeneration pathways including tau and inflammation targets, with Amgen exploring biotech synergies. Sanofi S.A. expanded via $470 million Vigil Neuroscience buyout in May 2025 for TREM2 agonist VG-3927 in Phase II, following earlier investments, while AbbVie Inc. acquired Aliada Therapeutics for $1.4 billion in 2024, gaining ALIA-1758 for blood-brain barrier delivery of anti-amyloid antibodies. These companies drive market growth from $6.41 billion in 2025 to $19.3 billion by 2034 at 13.03% CAGR, fueled by acquisitions, innovations, and collaborations amid global prevalence surges.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.